menu
    • menu
    [{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"},{"orgOrder":0,"company":"OrphoMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ORP-101","moa":"Partial mu receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"OrphoMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"OrphoMed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrphoMed \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for ORP-101

    Menu

    ORP-101

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OrphoMed

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            OrphoMed

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORP-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients

                            Details : ORP-101 is a new chemical entity designed to confer peripheral partial μ agonist and full κ receptor antagonist activity, enabling treatment of both IBS-D symptoms of dysmotility and pain without the risk of sphincter of Oddi spasm or pancreatitis.

                            Brand Name : ORP-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 14, 2021

                            Lead Product(s) : ORP-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OrphoMed

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            OrphoMed

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORP-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients

                            Details : OrphoMed announced that its ORP-101 molecule successfully cleared its first interim futility analysis in a Phase 2 clinical trial for treatment of irritable bowel syndrome with diarrhea (IBS-D).

                            Brand Name : ORP-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 26, 2021

                            Lead Product(s) : ORP-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            OrphoMed

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            OrphoMed

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORP-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D

                            Details : OrphoMed paused screening of new patients on March 27, 2020, in response to the COVID-19 pandemic. Now the company announces resumption of patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 02, 2020

                            Lead Product(s) : ORP-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            OrphoMed

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            OrphoMed

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORP-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D

                            Details : OrphoMed has paused new patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D) in response to the COVID-19 pandemic.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 31, 2020

                            Lead Product(s) : ORP-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            OrphoMed

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            OrphoMed

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORP-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020

                            Details : ORP-101 currently in phase 2 study for treatment of irritable bowel syndrome with diarrhea.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 19, 2020

                            Lead Product(s) : ORP-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth